Athens Medical CentreSTU:ACS +0.63%60 EBITDA Margin % is 7.81% as of Dec. 2025, which is 43% below its 10-year median of 13.65. GuruFocus rates STU:ACS with a GF Score™ of 60/100 and a GF Value™ of €1.93. The stock has 8 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Athens Medical Centre ranks worse than 50.6% on this metric.
Athens Medical Centre (STU:ACS) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Athens Medical Centre EBITDA Margin % Related Terms
Athens Medical Centre EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Athens Medical Centre's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:ACS vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Athens Medical Centre's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Athens Medical Centre EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Athens Medical Centre's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Athens Medical Centre's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Athens Medical Centre (STU:ACS) has a EBITDA Margin % of 7.81% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Athens Medical Centre and its competitors. This is 43% below median its historical median of 13.65. Over the past decade, Athens Medical Centre's EBITDA Margin % has ranged from 10.08 to 15.39. According to the industry distribution chart, Athens Medical Centre ranks #338 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 50.6%.
Is Athens Medical Centre's EBITDA Margin % too high?
Athens Medical Centre's current EBITDA Margin % of 7.81% is 43% below median its 10-year median of 13.65. Over the past 10 years, this metric has ranged from a low of 10.08 to a high of 15.39. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Athens Medical Centre's value of 7.81% is 23.5% below this industry median. Based on the distribution chart, Athens Medical Centre ranks #338 out of 668 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Athens Medical Centre has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Athens Medical Centre's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Athens Medical Centre ranks #338 out of 668 companies for EBITDA Margin %. This places Athens Medical Centre in the lower half of its industry. The industry median EBITDA Margin % is 10.21. Athens Medical Centre's value of 7.81% is 23.5% below this benchmark. Historically, Athens Medical Centre's own EBITDA Margin % has ranged from 10.08 to 15.39 over the past decade. While the company's 10-year median is 13.65 vs. the industry median of 10.21, Athens Medical Centre has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Athens Medical Centre's current EBITDA Margin % of 7.81% is 23.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Athens Medical Centre and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Athens Medical Centre's current EBITDA Margin % is 7.81%, which is 43% below median its own 10-year median of 13.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Athens Medical Centre stock overvalued right now?
Athens Medical Centre (STU:ACS) has a current EBITDA Margin % of 7.81%. The stock's GF Value™ is €1.93, compared to a current price of €1.59 — trading 17.9% below its estimated fair value. The current EBITDA Margin % is 7.81%, which is 43% below median its 10-year median of 13.65 and 23.5% below the Healthcare Providers & Services industry median of 10.21. Athens Medical Centre's overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Athens Medical Centre (STU:ACS), the current EBITDA Margin % is 7.81% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Athens Medical Centre (STU:ACS) Overvalued in 2026?
Based on GuruFocus' analysis, Athens Medical Centre stock appears to be undervalued.
The current stock price of €1.59 is trading 17.9% below its estimated GF Value™ of €1.93.
Key valuation signals for STU:ACS:
EBITDA Margin %: 7.81% (43% below median its 10-year median of 13.65)
GF Value™: €1.93 vs. price of €1.59 (17.9% below fair value)
Industry Position: 23.5% below the Healthcare Providers & Services median (#338 of 668)
No single metric tells the full story. See the STU:ACS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Athens Medical Centre SA engages in the provision of healthcare services. It includes medical research and methods of treatment, training, and selection of executives and staff on behalf of the hospitals and importation of medical tools, instruments, machinery, and automated devices for the hospitals. Its offering includes medical services in such specializations as pathology, cardiology, general surgery, plastic and vascular surgery, orthopedic, physiotherapy, ophthalmology, urology, neurosurgery, thoracic, pediatric, dermatology, endocrinology and stomatology. The company operates in Domestic healthcare service, Healthcare service provided abroad (Romania) and Sale of medical tools & sanitary/health equipment segment.
60GF Score
Get the complete analysis for STU:ACS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:ACS has been successfully added to your 
